Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.20452/pamw.16048 http://scihub22266oqcxt.onion/10.20452/pamw.16048 34180610!ä!34180610 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34180610&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pol+Arch+Intern+Med 2021 ; 131 (9): 802-807 Nephropedia Template TP {{tp|p=34180610|t=2021. Should we supplement zinc in COVID-19 patients? Evidence from a meta-analysis |pdf=|usr=}}{{34180610}} gab.com Text Should we supplement zinc in COVID-19 patients Evidence from a meta-analysis JO: Pol Arch Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=34180610 #FOAvip INTRODUCTION: Preliminary retrospective reports showed that zinc supplementation may decrease mortality in patients with COVID-19, postulating the potential therapeutic efficacy of zinc in the management of the disease. OBJECTIVES: We sought to summarize the studies published to date regarding the antiviral activity of zinc in patients with COVID-19. PATIENTS AND METHODS: A meta-analysis was performed to compare the outcomes of hospitalized patients receiving zinc supplementation and those treated with standard care. The primary outcome was survival to hospital discharge. Secondary outcomes were in-hospital mortality and length of stay in hospital or intensive care unit (ICU). RESULTS: Data relating to 1474 patients included in 4 studies were analyzed. Survival to hospital discharge was 56.8% in the zinc group compared with 75.9% in the nonzinc group (P = 0.88). In-hospital mortality was 22.3% in the zinc group compared with 13.6% in the standard care group (P = 0.16). The mean (SD) length of hospital stay was 7.7 (3.7) days in the zinc group and 7.2 (3.9) days in the standard treatment group (P <?0.001). The mean (SD) length of ICU stay was 4.9 (1.7) days in the zinc group and 5.8 (1.9) days in the standard care group (P = 0.009). CONCLUSIONS: Zinc supplementation did not have any beneficial impact on the course of COVID-19 evaluated as survival to hospital discharge and in-hospital mortality. The zinc-supplemented group had longer hospital stay despite shorter ICU stay. At present, there are no evidence-based data to support routine zinc supplementation in patients with COVID-19. Twit Text FOAVip Should we supplement zinc in COVID-19 patients Evidence from a meta-analysis ????Pol Arch Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=34180610 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34180610 #FOAvip English Wikipedia <ref>{{Cite pmid|34180610}}</ref> Should we supplement zinc in COVID-19 patients? Evidence from a meta-analysis #MMPMID34180610 Szarpak L; Pruc M; Gasecka A; Jaguszewski MJ; Michalski T; Peacock FW; Smereka J; Pytkowska K; Filipiak KJ Pol Arch Intern Med 2021[Sep]; 131 (9): 802-807 PMID34180610show ga INTRODUCTION: Preliminary retrospective reports showed that zinc supplementation may decrease mortality in patients with COVID-19, postulating the potential therapeutic efficacy of zinc in the management of the disease. OBJECTIVES: We sought to summarize the studies published to date regarding the antiviral activity of zinc in patients with COVID-19. PATIENTS AND METHODS: A meta-analysis was performed to compare the outcomes of hospitalized patients receiving zinc supplementation and those treated with standard care. The primary outcome was survival to hospital discharge. Secondary outcomes were in-hospital mortality and length of stay in hospital or intensive care unit (ICU). RESULTS: Data relating to 1474 patients included in 4 studies were analyzed. Survival to hospital discharge was 56.8% in the zinc group compared with 75.9% in the nonzinc group (P = 0.88). In-hospital mortality was 22.3% in the zinc group compared with 13.6% in the standard care group (P = 0.16). The mean (SD) length of hospital stay was 7.7 (3.7) days in the zinc group and 7.2 (3.9) days in the standard treatment group (P |*COVID-19[MESH] |Dietary Supplements[MESH] |Humans[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]Should we supplement zinc in COVID-19 patients? Evidence from a meta-a(epmc).pdf DeepDyve Pubget Overpricing